{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T03:48:01Z","timestamp":1778212081904,"version":"3.51.4"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Prasat Neurological Institute, Department of Medical Services, Ministry of Public Health, Thailand."}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0229028","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T13:33:09Z","timestamp":1581514389000},"page":"e0229028","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8183-348X","authenticated-orcid":true,"given":"Saharat","family":"Aungsumart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Metha","family":"Apiwattanakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,2,12]]},"reference":[{"key":"pone.0229028.ref001","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"VA Lennon","year":"2004","journal-title":"Lancet"},{"key":"pone.0229028.ref002","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"DM Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"pone.0229028.ref003","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange","volume":"22","author":"H Abboud","year":"2016","journal-title":"Mult Scler"},{"key":"pone.0229028.ref004","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.msard.2017.02.015","article-title":"Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literature","volume":"13","author":"S Aungsumart","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"pone.0229028.ref005","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"M Bonnan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"pone.0229028.ref006","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.4103\/0972-2327.164818","article-title":"Therapy of NMO spectrum disorders","volume":"18","author":"A Biswas","year":"2015","journal-title":"Ann Indian Acad Neurol"},{"key":"pone.0229028.ref007","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"MA Mealy","year":"2014","journal-title":"JAMA Neurol"},{"key":"pone.0229028.ref008","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2015.02.012","article-title":"Analysis of the treatment of neuromyelitis optica","volume":"351","author":"J Torres","year":"2015","journal-title":"J Neurol Sci"},{"key":"pone.0229028.ref009","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints","volume":"22","author":"IH Jeong","year":"2016","journal-title":"Mult Scler"},{"key":"pone.0229028.ref010","unstructured":"Vacharin P (2013) Working Group on the Guidelines for Health Technology Assessment in Thailand (2nd ed). Guidelines for health technology assessment in Thailand (2nd ed) Nonthaburi, Thailand."},{"key":"pone.0229028.ref011","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"SH Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"pone.0229028.ref012","article-title":"Cost-effectiveness of plasmapheresis in central nervous system inflammatory disease","author":"M Apiwattanakul","year":"2016","journal-title":"Prasat neurological institute, Department of medical services, Ministry of public health"},{"key":"pone.0229028.ref013","unstructured":"Drug and Medical Supply Information Center. Reference drug price Ministry of Public Health 2014 [cited October 1, 2016]. http:\/\/dmsic.moph.go.th\/dmsic\/index.php?p=1&id=1 (accessed Septempber 1, 2019)."},{"key":"pone.0229028.ref014","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Z Nikoo","year":"2017","journal-title":"J Neurol"},{"key":"pone.0229028.ref015","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis","volume":"73","author":"V Damato","year":"2016","journal-title":"JAMA Neurol"},{"key":"pone.0229028.ref016","unstructured":"Tratment outcome and complication of patient with Neuromyelitis optica sprectrum disorder in Prasat neurological instutute (May 2016-May 2018). Unpublished raw data."},{"key":"pone.0229028.ref017","unstructured":"The World Health Organization. Life tables by country: Thailand: The World Health Organization; 2014 [cited October 1, 2016]. http:\/\/apps.who.int\/gho\/data\/?theme=main&vid=61640 (accessed September 1, 2019)."},{"key":"pone.0229028.ref018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000445997","article-title":"Long-Term Survival Following Traumatic Brain Injury: A Population-Based Parametric Survival Analysis","volume":"47","author":"GW Fuller","year":"2016","journal-title":"Neuroepidemiology"},{"key":"pone.0229028.ref019","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.msard.2018.07.004","article-title":"Health utilities of patients with multiple sclerosis and neuromyelitis optica spectrum disorders in Thailand","volume":"24","author":"S Siritho","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"pone.0229028.ref020","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ene.13186","article-title":"Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder","volume":"24","author":"H Chen","year":"2017","journal-title":"Eur J Neurol"},{"key":"pone.0229028.ref021","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder","volume":"385","author":"Y Yang","year":"2018","journal-title":"J Neurol Sci"},{"key":"pone.0229028.ref022","unstructured":"Thailand\u2014World Bank Open Data\u2014World Bank Group 2018, July 21. Retrieved from https:\/\/data.worldbank.org\/country\/thailand."},{"key":"pone.0229028.ref023","volume-title":"Prevalence of Idiopathic Inflammatory Demyelinating Central Nervous System Disorder in Thailand","author":"N Prayoonwiwat","year":"2013"},{"key":"pone.0229028.ref024","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jns.2017.08.3005","article-title":"Prognostic factors for first relapse in Thai patients with neuromyelitis optica spectrum disorder","volume":"381","author":"K Suksuchano","year":"2017","journal-title":"Journal of the Neurological Sciences"},{"key":"pone.0229028.ref025","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jns.2012.07.014","article-title":"Diagnostic utility of NMO\/AQP4-IgG in evaluating CNS inflammatory disease in Thai patients","volume":"320","author":"M Apiwattanakul","year":"2012","journal-title":"J Neurol Sci"},{"key":"pone.0229028.ref026","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/1352458515602337","article-title":"Efficacy of rituximab in refractory neuromyelitis optica","volume":"22","author":"N Collongues","year":"2016","journal-title":"Mult Scler"},{"key":"pone.0229028.ref027","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"H Zephir","year":"2015","journal-title":"J Neurol"},{"key":"pone.0229028.ref028","first-page":"1","article-title":"Cost-Utility Analysis of Multiple Sclerosis Treatment in Thailand","author":"C Chanatittarat","year":"2018","journal-title":"Int J Technol Assess Health Care"},{"key":"pone.0229028.ref029","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"DM Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"pone.0229028.ref030","article-title":"Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence","author":"T Akaishi","journal-title":"Neurol Neuroimmunol Neuroinflamm 7"},{"key":"pone.0229028.ref031","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response","volume":"88","author":"JP Stellmann","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"pone.0229028.ref032","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1177\/1352458519832249","article-title":"Disease-modifying therapies should be stopped in NMOSD patients in remission\u2013No","volume":"25","author":"DL Rotstein","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"key":"pone.0229028.ref033","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1177\/1352458519829694","article-title":"Disease-modifying therapies should be stopped in NMOSD patients in remission\u2013Yes","volume":"25","author":"E Shosha","year":"2019","journal-title":"Multiple Sclerosis Journal"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0229028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T13:33:25Z","timestamp":1581514405000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0229028"}},"subtitle":[],"editor":[{"given":"Massimo","family":"Filippi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,2,12]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0229028","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,12]]}}}